Solventum Reports Third Quarter 2026 Financial Results

Solventum reported Q3 2026 sales of $1.949 billion, down 7.0% reported and 2.8% organically; adjusted diluted EPS was $1.45, down 3.6% year over year. The company raised its full-year adjusted EPS outlook to $7.20–$7.30 from $7.10–$7.20 and expects organic sales growth toward the high end of its +2.5%–+3.0% range; free cash flow guidance remains $200 million–$300 million. Quarterly free cash flow was $97 million, ahead of expectations partly due to an IEEPA tariff refund, while ERP cutovers were completed and about 90% of 3M transition service agreements had been exited.

Analysis

SOLV — earnings read-through: The setup is better than the reported-sales decline suggests, but the quality of the improvement is mixed. Management’s ERP pull-forward explanation makes the quarter’s organic decline plausibly timing-related; the test is whether orders normalize next quarter, not whether the 630-bp drag is accepted at face value. Segment dispersion matters more: wound care and Health Information Systems are growing, while Infection Prevention/Surgical Solutions and Dental are contracting. This makes a broad-based recovery less certain and puts greater weight on wound-care integration and HIS execution.

The EPS guide increase is supportive, but adjusted operating margin fell year over year, and quarterly free cash flow benefited from a tariff refund; nine-month free cash flow remains negative. Investors should therefore avoid extrapolating either the EPS raise or the cash-flow beat until underlying conversion is clearer. The large gap between GAAP and adjusted operating profit also leaves earnings quality and recurring separation/restructuring costs as valuation risks.

Horizon: Near term, the post-close call is the key catalyst: listen for order normalization, tariff exposure, and a bridge from adjusted earnings to cash. Over 1–3 months, confirmation of demand recovery and lower transition costs could support a rerating. Over 6–18 months, a potential HIS separation may sharpen the portfolio story, but stranded costs and execution could offset value. Contrarian read: the quarter is not simply an ERP miss, but the bullish guide may be getting more credit than cash generation and margin trends warrant. Valuation and current price are not supplied, so risk/reward cannot be quantified.

Key Decisions for Investors

• Do not chase SOLV before management’s call. Treat order normalization as unverified until the next quarter shows a recovery in organic sales, particularly in Infection Prevention/Surgical Solutions and Dental.
• Watch for a long entry after the call or on a pullback only if management substantiates the high-end sales outlook with normalized orders, stable adjusted margins, and improving cash conversion. Upside would come from execution and potential HIS separation; downside is continued segment weakness, persistent costs, or weaker cash generation.
• Falsify the recovery thesis if next-quarter organic sales fail to rebound after the stated ERP timing effect, adjusted operating margin continues to deteriorate, or full-year free-cash-flow guidance is cut. Verify the tariff-refund amount and the remaining recurring costs before underwriting cash-flow improvement.